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J. Demetrius, P. Randhawa. R.L. Simmons, T.R. Hakala, and T.E. Starzl 
THE USE of cyclosporine (CyA) has resulted in signif-icantly improved graft survival rates in renal trans-
plantation. 1-5 However. the incidence of allograft rejection 
with CyA remains as high as 69%.5 Although CyA mono-
therapy has proven feasible in some studies.6 recent at-
tempts to use Cy A alone in kidney transplant recipients 
have shown some significant disadvantages. namely in-
creased severity of rejection episodes and more pro-
nounced nephrotoxicity.s FK 506 is an experimental im-
munosuppressant that has yielded encouraging results in 
early trials of liver. heart. and. more recently. renal 
transplantation. 7-11 The apparent advantages of FK 506 in 
these early expenences include the ability to taper steroids 
aggressively to the point of permitting FK 506 monother-
apy in as many as 60% of renal transplant recipients with 
no increased risk of rejection episodes. II FK 506 has also 
been used successfully to salvage liver transplants reject-
ing under CyA immunosuppressionY We have recently 
begun evaluating the utility of FK 506 conversion in renal 
allograft recipients with failing grafts on Cy A. A total of 35 
patients were entered into this pilot study. the results of 
which are reponed herein. 
MATERIALS AND METHODS 
Patients 
There were 20 male patients and 15 females. with a mean age of 
32.6::: 14 years lrange 8 to 73 years'. Twenty-elght patients had 
undergone pnmary renal transplantation and seven had been 
retransplanted 15 second. I third. and I fourth transplants I. 
Twenty-four were recipients of cadavenc renal transplants (CAD) 
and II were from living-related donors I LRD). 
Indications for FK 506 ConversIon 
Patients considered for conversion to FK 506 had an initial 
diagnosis of uncontrolled rejection and/or other complications 
aSSOCiated with CyA and/or steroid therapy (Table I). Such 
complications included postoperative hypertension (diastolic 
blood pressure > 100 mm Hg despite diuretics' and steroid-
Induced diabetes mellitus. In the early part of the series. patients 
with chronic rejection on CyA therapy were also considered for 
FK 506 conversion. Prior to FK 506 conversion. maintenance 
immunosuppression consisted of CyA and prednisone in all pa-
tients. with (n = 16' or without (n = 19) azathioprine tAZA). All 
23 patients with the diagnosis of acute rejection had additionally 
received bolus high-dose steroid therapy, and nine of these 139%) 
had received one tn = 7) or two tn = 2) courses of OKT3 prior to 
FK 506 conversion. Sixteen pauents were referred to us for FK 
506 conversion from other centers where they were deemed to be 
losing their grails: 19 pauents were ent~red from our own institu-
Table 1. Conversion From CyA to FK 506 In 35 ReMI 
T,.,..,..,.. R ....... 
Indication lor FK S06 ConvenllOl'l 
Ongoing acute rejection" 
Chronic rejection 
CyA toXIcity 
Steroid complicatIOns! 
Total 
No. PatIenIIl%) 
24 (69) 
6 (17) 
3 (9) 
2 (5) 
35 
No. 5ucceahi 
~E%F 
17 (71) 
0(0) 
1 (33) 
2 (100) 
20 
'Two pabents had seven! yaSQ.I1ar r8f8CIIOI1 wdh iSChemIC infarction and failed 
conversaon. 
tOne oatl8nl had stlllOld-tndUC8d insuhn c:Iependent diabetes, and one pallen! 
wlSned to be tapered off preanrsone because of m8llc1lCl obeStIy. 
lion. All patients had received CyA doses maximized to tolerable 
levels. 
Preconversion Diagnostic Evaluation 
All patients considered for conversion to FK 506 were subjected 
to Doppler ultrasound and radionuclide flow study of the renal 
allograft to rule out a technical cause of allograft dysfunction. 
Renal allograft biopsies were performed in all but the two patients 
who were converted to FK 506 because of steroid-related com-
plications. The pathologic diagnosis prior to conversion was 
chrome rejection in six patients. interstitial fibrosis in three. 
severe vascular (humoral) rejection in two. and acute cellular 
rejection tACR) in 22. Two of the patients with biopsy-proven 
ACR also had components of vascular rejection. 
FK 506 Conversion Therapy 
Because of previous evidence of adverse effects with combined 
FK 506 and Cy A therapy In liver allograft recipients. 12 all patients 
underwent a simple switch ("clean conversion") from CyA to FK 
506. All patients were given a standard daily oral dose of 0.3 
mg/kg/d in divided doses every 12 hours starting 12 hours after the 
last eyA dose had been administered. In addition, II patients 
received parenteral doses of FK 506 of 0.025 to 0.1 mg/kg/d 
overlapping with the first I to 4 days of oral therapy. Dose 
adjustments of FK 506 were based upon monitoring of serum 
trough levels by ELISA I) to achieve a 12-hour trough level of 1.0 
to 2.0 ng/mL, and also by adjustment according to clinical and 
biochenucal parameters. 
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RESULTS 
Successful conversion from CyA to FK 506 was defined as 
a return to baseline serum creatinine (SCR). and/or im-
provement on postconversion renal allograft biopsy. 
and/or freedom from dialysis if the patient was dialysis-
dependent at the time of conversion. Of the 35 patients 
entered into this study. successful conversion according to 
these criteria was achieved in 20 (57%). Early in this 
series. FK 506 conversion was attempted in six patients 
with evidence of chronic rejection on preconversion bi-
opsy, all of whom subsequently lost their grafts. Of the 
remaining 29. one patient without rejection desired FK 506 
conversion in order to eliminate steroid therapy. This 
patient has since been tapered to 2.5 mg of prednisone 
daily and is now 7 months postconversion. A second 
patient with steroid-induced insulin-dependent diabetes 
mellitus is currently taking no prednisone and is requiring 
- -=. significantly less insulin. Of the remaining 27 patients. 24 
had ongoing acute rejection on preconverslOn biopsy and 
three had interstitial fibrosis. Of the 24 cases with acute 
rejection. 17 (71%) were successfully rescued. Two of 
these successes had evidence of a vascular component of 
rejection on preconversion biopsy. Eleven patients with 
acute rejection prior to conversion had failed at least one 
course ofOKT3 (average length oftreatment 10 days) prior 
to FK 506 conversion. which was carried out at a median 
of IS days following the last dose of OKTJ. Nine patients 
in this series (26%) were already dialysis-dependent at the 
time of conversion. Of these. six patients now have 
functioning grafts with serum creatinines of 2.1. 2.3. 2.4. 
2.5.2.5. and 6.6 mgidL. respectively. The clinical course 
of one such patient is depicted in Fig 1. 
Successful conversion was achieved in 12 of 24 (50%) 
CAD and S of II (73%) LRD recipients. There was a 
slightly greater proportion of patients with ACR as the 
preconversion diagnosis in the LRD group (Sill. 73%) 
compared to the CAD group (16/24.67%). Patients initially 
immunosuppressed with CyA and prednisone (n = 19) or 
CyA. prednisone. and AZA (n = 16) had equivalent 
success rates of 5S% and 56%. respectively. Of the 28 
primary transplantations. 18 (64%) were successfully con-
verted: two of the five retransplants (40%) were successes. 
Of 16 patients referred from other centers for FK 506 
conversion. 13 (81%) were rescued compared with 7/19 
(37%) successes in patients from our own institution. As 
described earlier. the first six patients from our own 
institution were early attempts that all failed conversion 
for chronic rejection. which in retrospect was most likely 
"Z an ill-advised indication for conversion to FK 506. 
Morbidity and Mortality 
There were three deaths in this series. all occurring in 
patients whose grafts had been lost. One patient died 8 
months postconversion while on dialysis (unknown etiol-
ogy), one from overwhelming sepsis at 7 months. and one 
patient suffered a massive fatal intracranial hemorrhage 4 
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Fig 1. Clinical course of patient no. 27. The patient is a 30-year-
old male with ESRD secondary to a connective tissue disorder with 
0% panel reactive antibody undergoing primary transplantation. A 
severe rejection occurred 4 weeks after transplantation. which did 
not respond to a course of high-dose corticosteroids. The patient 
required dialysis on five occasions after the rejection episode 
began. He receIVed two doses of OKT3 but had a severe reaction 
to the drug (disorientatJon. seizures. fluid overload) and this was 
discontinued. He was switched to FK 506 on day 33 following 
transplantation. The patient currently has a functioning graft with a 
SCR of 1.7 mg/dL. 
months after conversion. The remaining complications in 
this series are shown in Table 2. Three patients referred for 
conversion to FK 506 had experienced prior complica-
tions. One patient had suffered a pel1'orated duodenal ulcer 
after high-dose bolus steroid therapy for rejection. Follow-
Table 2. FK 506 Salvage Therapy: Complications 
Pre-FK 506 ConversKll\ 
Perforated duodenal ulcer 
CMV Gastritis 
Urine leak 
No. Post.fK 506 Conllel'SlOl1 
CMV pneumonitis 
Diabetes-oral medication 
Diabetes-msulln dependent 
EpistaxiS 
Cecal perlorallon 
HypertenSIOn 
Bactenal pneumonia 
No. 
:d 
;1\ 
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Fig 2. Renal function in patients with functioning allografts fol· 
lowing conversion from eyA to FK 506. excluding those patients 
on dialysis at the time of conversion. 
ing surgical correction of this complication. she continued 
to have rejection of the allograft. This patient was subse-
quently switched successfully to FK 506 with no further 
complications. A second patient developed CMV gastntis 
following treatment of rejection with high-dose steroids 
and OKT3. He was converted to FK 506 while being 
treated with ganciclovir. with successful results. A third 
patient referred for FK 506 conversion had developed a 
ureteral leak 29 days posttransplant. The patient was 
successfully switched to FK 506 2 months after ureterone-
ocystostomy following a severe rejection episode that was 
resistant to both high-dose steroids and a to-day course of 
OKT3. Other complications following FK 506 conversion 
are listed in Table 2. !'Jone of these resulted in any 
mortality and could not be directly related to FK 506 
conversion. 
Renal Function 
The mean SCR prior to FK 506 conversion in the success-
ful switches was 3.2 :!: 2.0 mgidL. excluding the six 
patients who were on dialysis at the time of FK 506 
conversion. The average SCR after FK 506 conversion 
was 2.3 :!: 1.2 mgldL. with all 20 grafts functioning 
(including the six on dialysis at the time of conversIOn). 
Excluding the six patients on dialysis at the time of 
conversion. the average SCR post-FK 506 conversion was 
1.9 :!: 0.5 mg;dL. The time course of improvement in renal 
function in relation to FK 506 conversion is illustrated in 
Fig 2. 
Postconverslon Immunosuppression 
All patients switched from Cy A to FK 506 were taking 
prednisone prior to conversion (average dose 17.7 :!: 9.9 
mg;d). At last follow-up (mean 8.9 months). the average 
prednisone dose for the 20 patients with functioning grafts 
is 6.6 :!: 6.1 mgld. All 20 patients successfully convened 
remain on FK 506. with seven patients (35%) on FK 506 
monotherapy. 
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Biochemistry 
Mean serum uric acid in the 35 patients converted to FK 
506 was 7.5 :!: 3.5 mg;dL preconversion and 7.9 :!: 2.1 
postconversion. Glucose was 100.3 :!: 21.1 mgldL precon-
version and 111.8 :!: 65.1 mgldL postconversion. One 
patient became insulin dependent following conversion 
and a second patient requires an oral hypoglycemic agent. 
Mean cholesterol and trigiycerides were 189.0 :!: 42.0 and 
225.8 :!: 107.4 preconversion and 198.0 :!: 8.2 and 222.0 :!: 
95.7 postconversion. respectively. 
DISCUSSION 
Despite the enhanced graft survival since the advent of 
eyA in renal transplantation. the incidence of rejection 
episodes remains high in most reponed series. I- 5 One of 
the primary stated aims of mUltiple drug regimens for 
immunosuppression is the achievement of less tOXicity 
without an increased risk of rejection. Unfortunately. even 
with triple therapy based on Cy A. rejection episodes occur 
with enough frequency and severity as to result in even the 
most conservative practitioner occasionally overimmuno-
suppressing with excessive steroids and/or antilymphocyte 
preparations. with their attendant complications. It would 
be preferable to use an alternative immunosuppressive 
agent that was potent enough to reverse recalcitrant rejec-
tion without resorting to the use of excessive doses of 
steroids and antilymphocyte preparations. The results of 
this study indicate that FK 506 may possess these advan-
tages. 1 n 17/24 (71 %) of the patients who were losing their 
grafts owing to ongoing acute rejection. FK 506 conversion 
resulted in graft salvage. Ten of these 17 patients (59%) 
had alreadv failed OKT3 treatment, and all 17 patients had 
been prevlOuslv treated with bolus steroid therapy. Steroid 
tapering was accomplished in the majority of these patients 
postconversion. and seven patients are currently on FK 
506 monotherapy, These results illustrate the potency of 
FK 506 as an immunosuppressant. but the incidence and 
severity of complications after FK 506 conversion are also 
quite tolerable. In this regard. FK 506 appears to be unique 
as a novel nonsteroidal immunosuppressant that can be 
used to reverse acute rejection in renal transplantation. 
Other than its proven in vitro potency, It is not clear what 
properties of FK 506 other than inhibition of IL-2 and IL-4 
synthesis might account for these observations. Recent 
studies by Wang et al 14 suggest that FK 506 spares fL-lO 
production: perhaps other mechanisms are also involved 
and will await further investigation. 
In conclusion. FK 506 can be used to salvage renal 
allograits failing Cy A-based immunosuppression due to 
llngoing acute rejection. In certam instances. sterOid ther-
apy may be entirely eliminated following FK 506 conver-
,ion while preserving adequate immunosuppression and 
graft function. 
~K 
FK 506 CONVERSION 
REFERENCES 
I. The Canadian Multi-Center Transplant Study Group: N Eng! 
J Med 309:809. 1983 
2. Sommer BG. Henry M. Ferguson. RM: Transplantation 
43:8!!. 1987 
3. Tilney NL. Milfor EL. Carpenter CB. et a1: Transplant Proc 
l8(suppl 1):179. 1986 
4. Matas AT. Tellis VA. Quinn TA. et a1: Transplantation 
45:406. 1988 
5. Tarantino A. Aroldi A. Stucchi L. et a1: Transplantation 
52:!!3. 1991 
6. European Multicentre Trial Group: Lancet 2:986. 1983 
, 
3081 
7. Todo S. Fung JJ. Demelris AJ. ct a1: Transplant Proc 22:13. 
1990 
8. Starzi TE. Todo S. Fung J. ct a1: Lancet 2:1000. 1989 
9. Starzi TE. Fung J. Jordan M. et a1: JAMA 264:63. 1990 
10. Armitage JM. Kormos RL. Griffith BP. ct a1: Transplant 
Proc 23:1149. 1991 
11. Shapiro R. Jordan M. Fung J. ct a1: Transplant Proc 23:920. 
1991 
12. Fung JJ. Todo S. Jain A. et a1: Transplant Proc 22(suppl 
1):6. 1990 
13. Tamura K. Kobayashi M. Hashimoto K. ct a1: Transplant 
Proc 19(suppl 6):23. 1987 
14. Wang S. Zcevi A. Tweardy DJ. ct al: Transplant Proc 23. 
(this issue). 1991 
